CME Presentations




  • Charles B. Nemeroff, MD, PhD

    Charles B. Nemeroff, MD, PhD

    Charles B. Nemeroff, MD, PhD

    Matthew P. Nemeroff Professor and Chair, Department of Psychiatry and Behavioral Sciences

    Charles B. Nemeroff, MD, PhD, is the Leonard M. Miller Professor and Chairman of the Department of Psychiatry and Behavioral Sciences, and clinical director of the Center on Aging at the University of Miami Miller School of Medicine in Florida. He chairs the American Psychiatric Association (APA) Research Colloquium for Young Investigators and the APA Work Group on Biomarkers and Novel Treatments. He is past president of the American College of Psychiatrists (ACP) and the American College of Neuropsychopharmacology (ACNP), and is on the Scientific Advisory Board and Board of Directors of the American Foundation for Suicide Prevention (AFSP) and the Anxiety and Depression Association of America (ADAA). He earned his MD and PhD from the UNC School of Medicine in Chapel Hill, North Carolina.

CME Information

Changing the Treatment Paradigm in Schizophrenia: Customizing Antipsychotic Approach to Match Patient Needs

Global Logo PQH Logo


At the conclusion of this activity, participants will be able to:
  • Determine transitioning strategies between antipsychotic formulations in patients with schizophrenia
  • Identify clinical and physiological consequences of nonadherence and treatment discontinuation of antipsychotic therapy and strategies to address such issues
  • Assess the potential therapeutic benefits of newly approved antipsychotic formulations as well as agents being investigated for the treatment of schizophrenia
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Schizophrenia and Related Disorders Alliance of America (SARDAA)


This activity is supported by educational grants from Alkermes, Inc. and Noven Pharmaceuticals, Inc.


This activity was released on December 23, 2020 and is valid for one year. Requests for credit must be made no later than December 23, 2021.


The educational design of this activity addresses the needs of psychiatrists, family physicians, primary care physicians, internal medicine physicians, advanced practice providers, nurses, and pharmacists involved in the treatment of patients with schizophrenia.


Schizophrenia, a life-long disabling condition, is challenging to treat due to the cognitive and functional impairment that accompanies the disease. Antipsychotic therapy is the cornerstone of treatment for schizophrenia, but adherence is frequently poor, leading to suboptimal outcomes. In order to ensure that patients and their families and caregivers are able to achieve treatment goals, clinicians need to individualize antipsychotic treatments for each patient. In addition, health care providers need proven strategies to help convey to patients/caregivers the importance of adhering to antipsychotic regimens.

Join Dr. Charles B. Nemeroff for an exploration of the use of antipsychotic therapy to treat schizophrenia, including current treatment options, investigational agents, and associated safety and efficacy data. Patient / caregiver vignettes and a patient-advocacy video will highlight the patient voice and frame discussions of available resources for clinicians and patients. This important education will also describe the consequences of non-treatment and non-adherence to prescribed regimens, while reviewing strategies and tools to avoid these negative impacts, improve shared decision-making, and optimize patient outcomes.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 1 hour to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
Charles B. Nemeroff, MD, PhD
Matthew P. Nemeroff Professor and Chair
Department of Psychiatry and Behavioral Sciences
Mulva Clinic for the Neurosciences
Director, Institute of Early Life Adversity Research
Dell Medical School
The University of Texas at Austin
Consultant/Independent Contractor: ANeuroTech (division of Anima BV), Taisho Pharmaceutical, Inc., Takeda, Signant Health, Sunovion Pharmaceuticals, Inc., Janssen Research & Development LLC, Magstim, Inc., Navitor Pharmaceuticals, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Acadia Pharmaceuticals, Axsome, Sage, BioXcel Therapeutics, Silo Pharma, XW Pharma, Neuritek
Grant/Research Support: National Institutes of Health (NIH)
Advisory Board: ANeuroTech (division of Anima BV), Brain and Behavior Research Foundation (BBRF), Anxiety and Depression Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia CNS
Stock Shareholder: Xhale, Seattle Genetics, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness
Other/Royalty: Board of Directors: Gratitude America, ADAA, Xhale Smart, Inc.
Patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1) Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2)

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
Sandy Dimiterchik Nothing to disclose
Grace Lee Nothing to disclose
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Carole Drexel Nothing to disclose
Alissa Yost Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support: For any technical issues or issues with your CME Certificate, please contact PsychiatryCareLive at 877-394-1306 or at